“In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells” (2020) Brazilian Journal of Pharmaceutical Sciences, 56, p. e18254. doi:10.1590/s2175-97902019000318254.